Felbamate Articles
US FDA warns against use of PPI Prilosec with Plavix
18 November 2009
Carter-Wallace sold for $408 million
2 October 2001
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Higher-Priced Drugs Set To Expand Epilepsy Market
12 February 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Prospects For Glutamate Antagonists In Stroke
18 September 1995
NEW YORK STOCK COMMENT
21 November 1994
Felbatol Recommendation From FDA
10 October 1994
Carter-Wallace Abandons Drugs Research
10 October 1994
Quarterly Results From Smaller US Drug Firms
22 August 1994
NEW YORK STOCK COMMENT
15 August 1994
Carter Wallace To Stop Selling Felbamate?
15 August 1994
NEW YORK STOCK COMMENT
8 August 1994
Immediate Suspension of Felbatol Therapy Advised
8 August 1994
Felbatol Approval Marks Year At Carter-Wallace
1 August 1994
GEOGRAPHIC DIVERSITY KEY TO SCHERING-PLOUGH
11 July 1994
FELBAMATE GETS CPMP BACKING
4 April 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
THE DAWN OF A NEW ERA FOR EPILEPSY
27 September 1993
DUPONT MERCK TO PROMOTE LAMICTAL
16 August 1993
FELBATOL LAUNCH THIS MONTH
16 August 1993
FELBATOL IS APPROVABLE
2 August 1993
NEW HOPES FOR EPILEPSY TREATMENT
12 July 1993
SCHERING-PLOUGH NOW "MORE EFFICIENT"
10 May 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
FDA PANEL ENDORSES WALLACE'S FELBATOL
18 January 1993
PROMISING RESULTS FOR DEZINAMIDE
21 December 1992
"GREAT STRIDES" FOR SCHERING-PLOUGH
18 May 1992
SCHERING CORP TO MARKET FELBAMATE
13 April 1992
NEW DRUGS FOR EPILEPTICS
13 January 1992
Showing 1-33 of 33 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
